Screening tool for hollow-fiber bioreactor process development

Biotechnology Progress

Volumn 14, Issue 2, 1998, Pages 203-209

  Gramer, Micheal J ^a   Poeschl, Douglas M ^a  

^a Cellex Biosciences Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HOLLOW FIBER REACTOR; HYBRIDOMA; MICRO BIOREACTOR; PROCESS DEVELOPMENT; REACTOR DESIGN; REACTOR MONITORING;

ANTIBODIES; BIOREACTORS; COMPOSITION EFFECTS; FIBROUS MEMBRANES; MOLECULAR WEIGHT; SCREENING; SILICONES;

HOLLOW FIBER BIOREACTORS; MURINE HYBRIDOMAS;

ANIMAL CELL CULTURE;

EID: 0032031939     PISSN: 87567938     EISSN: None     Source Type: Journal    
DOI: 10.1021/bp9800081     Document Type: Article

References (13)

1. Hirschel, M. D.; Gruenberg, M. L. An Automated Hollow Fiber System for the Large Scale Manufacture of Mammalian Cell Secreted Product. In Large Scale Cell Culture Technology; Lydersen, B., Ed.; Hanser Publishers: New York, 1988; pp 113-144.
2. Maki, T.; Otsu, I.; O'Neil, J. J.; Dunleavy, K.; Mullon, C. J. P.; Solomon, B. A.; Monaco, A. P. Treatment of Diabetes by Xenogenic Islets without Immunosuppression: Use of a Vascularized Bioartificial Pancreas. Diabetes 1996, 45, 342-347.
3. Sielaff, T. D.; Hu, M. Y.; Amiot, B.; Rolling, M. D.; Rao, S.;McGuire, B.; Bloomer, J. R.; Hu, W.-S.; Cerra, F. B. Gel-Entrapment Bioartificial Liver Therapy in Galactosamine Hepatitis: J. Surg. Res. 1995, 59, 179-194.
4. Stahness, K. A.; Guatteo, E.; Janigro, D. A Dynamic Model of the Blood-Brain Barrier In Vitro. Neurotoxicology 1996, 17, 481-496.
5. Lister, P. D.; Prevam, A. M.; Sanders, C. C. Importance of β -lactamase Inhibitor Pharmacokinnetic in the Pharmacodynamics of Inhibitor-Drug Combinations: Studies with Piperaciilin-Tazobactum and Piperacillin-Sulbactam. Animicrob. Agents Chemother. 1997, 41, 721-727.
6. Moore, M. R.; Hamzeh, F. M.; Lee, F. E.-H.; Leitman, P. S. Activity of (s)-1-(3-Hydroxy-2-Phosphonylmethoxypropyl) Cytosine against Human Cytomegalovirus when Administered as a Single Bolus Dose and Continuous Infusion in In Vitro Cell Culture Perfusion System. Antimicrob. Agents Chemother: 1994, 38, 2404-2408.
7. Piret, J. M.; Cooney, C. L. Model of Oxygen Transport Limitations in Hollow Fiber Bioreactors. Biotechnol. Bioeng. 1991, 37, 80-92.
8. Schlapfer, B. S.; Scheibler, M.; Holtorf, A.-P.; Van Nguyen, H.; Pluschke, G. Development of Optimized Transfectoma Cell Lines for Production of Chimeric Antibodies in Hollow Fiber Cell Culture Systems. Biotechnol. Bioeng. 1995, 45, 310-319.
9. Jackson, L. R.; Trudel, L. J.; Fox, J. G.; Lipman, N. S. Evaluation of Hollow Fiber Bioreactors as an Alternative to Murine Ascites Production for Small Scale Monoclonal Antibody Production. J. Immunol. Methods 1996, 189, 217-231.
10. Sardonini, C. A.; DiBiasio, D. Investigation of the Diffusion-Limited Growth of Animal Cells Around Single Fibers. Biotechnol. Bioeng. 1992, 40, 1233-1242.
11. Molday, R. S.; MacKenzie, D. Monoclonal Antibodies to Rhodopsin: Characterization, Cross-Reactivity, and Application as Structural Probes. Biochemistry 1983, 22, 653-660.
12. Piret, J. M.; Cooney, C. L. Mammalian Cell and Protein Distributions in Ultrafiltration Hollow Fiber Bioreactors. Biotechnol. Bioeng. 1990, 36, 902-910.
13. Spector, A. A. The Transport and Utilization of Free Fatty Acids. Annu. N. Y. Acad. Sci. 1968, 149, 768-783.